P/E ratio for Orthofix Medical (OFIX)
P/E ratio as of April 2024 (TTM): -3.58
According to Orthofix Medical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.57924. At the end of 2022 the company had a P/E ratio of -20.9.
P/E ratio history for Orthofix Medical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -20.9 | 30.72% |
| 2021 | -16.0 | -104.47% |
| 2020 | 358 | -1271.14% |
| 2019 | -30.6 | -142.53% |
| 2018 | 71.9 | -55.31% |
| 2017 | 161 | -24.41% |
| 2016 | 213 | -181.42% |
| 2015 | -261 | 221.75% |
| 2014 | -81.2 | 476.75% |
| 2013 | -14.1 | -196.34% |
| 2012 | 14.6 | -141.92% |
| 2011 | -34.9 | -403.11% |
| 2010 | 11.5 | -46.79% |
| 2009 | 21.6 | -1984.99% |
| 2008 | -1.15 | -101.29% |
| 2007 | 89.2 | -176.7% |
| 2006 | -116 | -1437.98% |
| 2005 | 8.69 | -50.63% |
| 2004 | 17.6 | -37.1% |
| 2003 | 28.0 | 94.95% |
| 2002 | 14.4 | -37.31% |
| 2001 | 22.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Stryker Corporation SYK | 49.5 | -1,483.20% | 🇺🇸 USA |
 NuVasive NUVA | 73.6 | -2,156.61% | 🇺🇸 USA |
 Smith & Nephew
SNN | 21.3 | -694.63% | 🇬🇧 UK |
 Globus Medical GMED | 24.7 | -789.84% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.